Validation of the international medical prevention registry on venous thromboembolism bleeding risk score

Chest

Volumn 149, Issue 2, 2016, Pages 372-379

  Hostler, David C ^a   Marx, Elizabeth S ^a   Moores, Lisa K ^b   Petteys, Sarah K ^a   Hostler, Jordanna Mae ^a   Mitchell, Joshua D ^a   Holley, Paul R ^c   Collen, Jacob F ^d   Foster, Brian E ^a   Holley, Aaron B ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

Antibiotic therapy; Deep venous thrombosis; Pulmonary embolism

Indexed keywords

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL MEDICAL PREVENTION REGISTRY ON VENOUS THROMBOEMBOLISM BLEEDING RISK SCORE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; THROMBOSIS PREVENTION; VALIDATION STUDY; VENOUS THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED; FOLLOW UP; HEMORRHAGE; HOSPITAL PATIENT; INCIDENCE; MARYLAND; MIDDLE AGED; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; REGISTER; RISK FACTOR; STANDARDS; VERY ELDERLY;

ANTICOAGULANT AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; INCIDENCE; INPATIENTS; MALE; MARYLAND; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84958087761     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2842     Document Type: Article

References (26)

1. Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism(VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-764.
2. Stein PD, Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Clin Chest Med. 2010;31(4):611-628.
3. Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82(9):777-782.
4. Nicolaides A, Hull RD, Fareed J. The problem and the need for prevention. Clin Appl Thromb Hemost. 2013;19(2):121-122.
5. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938.
6. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996; 93(12):2212-2245.
7. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I4-I8.
8. Heit JACA, Anderson FA Jr. VTE Impact Assessment Group. Estimated annual number of incident and recurrent, nonfatal and fatal venous thromboembolism (VTE) events in the US [abstract]. Blood. 2005:106. Abstract 910.
9. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8): 943-953.
10. Nicolaides AN, Cardiovascular Disease E, Research T, et al. Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). Circulation. 2000;102:E126-E163.
11. Nicolaides A, Hull RD, Fareed J. Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie. Cost-effectiveness of prevention and treatment of VTE. Clin Appl Thromb Hemost. 2013;19(2):220-223.
12. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in Chest. 2012;142(6);1698 and Chest. 2012;141(4): 1129]. Chest. 2012;141(2-suppl):7S-47S.
13. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2-suppl):e195S-e226S.
14. Treasure T, Hill J.NICEguidance on reducing the risk of venous thromboembolism in patients admitted to hospital. J R Soc Med. 2010;103(6):210-212.
15. Mahan CE, Spyropoulos AC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health Syst Pharm. 2012;69(24):2174-2190.
16. Anderson FA Jr, Zayaruzny M, Heit JA, Cohen AT. behalf of the VTE Impact Assessment Group. Estimated annual number of US acute-care hospital inpatients meeting ACCP criteria for venous thromboembolism (VTE) prophylaxis. Blood. 2005:106. Abstract 903.
17. Tapson VF, Hyers TM, Waldo AL, et al; NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med. 2005;165(13):1458-1464.
18. Pendergraft T, Liu X, Edelsberg J, et al. Prophylaxis against venous thromboembolism in hospitalized medically ill patients. Circ Cardiovasc Qual Outcomes. 2013;6(1):75-82.
19. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(suppl 1):132S-175S.
20. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2-suppl):e419S-e494S.
21. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011;155(9):625-632.
22. Decousus H, Tapson VF, Bergmann JF, et al; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1): 69-79.
23. Streiff MB, Lau BD. Thromboprophylaxis in nonsurgical patients. Hematology Am Soc Hematol Educ Program. 2012;2012: 631-637.
24. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706-714.
25. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
26. Tapson VF, Decousus H, Pini M, et al; IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936-945.